Evidence for a new pathophysiological mechanism for coronary artery disease regression - Hepatic lipase-mediated changes in LDL density

被引:205
作者
Zambon, A
Hokanson, JE
Brown, BG
Brunzell, JD
机构
[1] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[2] Univ Washington, Div Cardiol, Seattle, WA 98195 USA
关键词
stenosis; lipoproteins; lipids; atherosclerosis;
D O I
10.1161/01.CIR.99.15.1959
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Small, dense LDL particles are associated with coronary artery disease (CAD) and predict angiographic changes in response to lipid-lowering therapy. Intensive lipid-lowering therapy in the Familial Atherosclerosis Treatment Study (FATS) resulted in significant improvement in CAD. This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy. Methods and Results-Eighty-eight of the subjects in FATS with documented coronary disease, apolipoprotein B levels greater than or equal to 125 mg/dL, and family history of CAD were selected for this study. They were randomly assigned to receive lovastatin (40 mg/d) and colestipol (30 g/d), niacin (4 g/d) and colestipol, or conventional therapy with placebo alone or with colestipol in those with elevated LDL cholesterol levels. Plasma hepatic lipase (HL), lipoprotein lipase, and LDL density were measured when subjects were and were not receiving lipid-lowering therapy. LDL buoyancy increased with lovastatin-colestipol therapy (7.7%; P<0.01) and niacin-colestipol therapy (10.3%; P<0.01), whereas HL decreased in both groups (-14% [P<0.01] and -17% [P<0.01] with lovastatin-colestipol and niacin-colestipol, respectively). Changes in LDL buoyancy and HL activity were associated with changes in disease severity (P<0.001). In a multivariate analysis, an increase in LDL buoyancy was most strongly associated with CAD regression, accounting for 37% of the variance of change in coronary stenosis (P<0.01), followed by reduction in apolipoprotein B1 (5% of variance; P<0.05). Conclusions-These studies support the hypothesis that therapy-associated changes in HL alter LDL density, which favorably influences CAD progression. This is a new and potentially clinically relevant mechanism linking lipid-altering therapy to CAD improvement.
引用
收藏
页码:1959 / 1964
页数:6
相关论文
共 53 条
[21]   Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women [J].
Gardner, CD ;
Fortmann, SP ;
Krauss, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (11) :875-881
[22]   ROLE OF PLASMA TRIGLYCERIDE IN THE REGULATION OF PLASMA LOW-DENSITY-LIPOPROTEIN (LDL) SUBFRACTIONS - RELATIVE CONTRIBUTION OF SMALL, DENSE LDL TO CORONARY HEART-DISEASE RISK [J].
GRIFFIN, BA ;
FREEMAN, DJ ;
TAIT, GW ;
THOMSON, J ;
CASLAKE, MJ ;
PACKARD, CJ ;
SHEPHERD, J .
ATHEROSCLEROSIS, 1994, 106 (02) :241-253
[23]   Small LDL, atherogenic dyslipidemia, and the metabolic syndrome [J].
Grundy, SM .
CIRCULATION, 1997, 95 (01) :1-4
[24]   A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol [J].
Guerra, R ;
Wang, JP ;
Grundy, SM ;
Cohen, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4532-4537
[25]  
HOKANSON JE, 1997, HDB LIPOPROTEIN TEST, V14, P267
[26]   HUMAN ADIPOSE-TISSUE LIPOPROTEIN-LIPASE - CHANGES WITH FEEDING AND RELATION TO POSTHEPARIN PLASMA ENZYME [J].
IVERIUS, PH ;
BRUNZELL, JD .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 249 (01) :E107-E114
[27]   Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients [J].
Jansen, H ;
Verhoeven, AJM ;
Weeks, L ;
Kastelein, JJP ;
Halley, DJJ ;
vandenOuweland, A ;
Jukema, JW ;
Seidell, JC ;
Birkenhager, JC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2837-2842
[28]  
KANNEL W B, 1981, Progress in Lipid Research, V20, P339, DOI 10.1016/0163-7827(81)90067-9
[29]  
KINNUNEN PKJ, 1983, ATHER REV, V11, P65
[30]   EVIDENCE FOR THE ROLE OF HEPATIC ENDOTHELIAL LIPASE IN THE METABOLISM OF PLASMA HIGH-DENSITY LIPOPROTEIN-2 IN MAN [J].
KUUSI, T ;
SAARINEN, P ;
NIKKILA, EA .
ATHEROSCLEROSIS, 1980, 36 (04) :589-593